Verastem, Inc. (VSTM) Release: Cancer Research Publication Highlights Importance Of Merlin Loss And Cancer Stem Cells In Mesothelioma
2/25/2014 9:24:34 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in the journal Cancer Research supports the scientific rationale for the Company’s ongoing development program of targeting cancer stem cells in mesothelioma. The paper, titled “Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53–miR-34a–c-Met Axis,” was co-authored by Verastem Head of Research Jonathan Pachter, Ph.D.
Help employers find you! Check out all the jobs and post your resume.
comments powered by